AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04284748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine physiotherapy program
Description: Anterior and lateral plan exercise (3x10 rep) Open kinetic quadriceps and hamstring strengthening exercise (3x10 rep) Lunge exercises on different ground (3x10 rep) Single leg squat exercise on different ground (3x10 rep) Anterior and lateral walking exercise in a squatting position with an exercise band (40 step) Balance and proprioceptive exercises
Study NCT01763736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: playlist per patient preference
Study NCT01594060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin, regular - act rapid
Description: 4 shots of regular insulin: 3 before meals and one at bedtime.
Study NCT01594060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glulisine, Insulin glargine
Description: 1 shot glargine at bedtime 3 shots glulisine before meals
Study NCT02390297 — intervention group
Intervention type: GENETIC
Intervention: Blood tests
Description: Collection of blood samples for general health (complete blood count) and Cal-1 specific analyses
Study NCT04455724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure incisional wound therapy
Description: A vacuum-style dressing system that is sealed in place over a surgical wound, applying constant negative pressure to the healing tissues.
Study NCT04455724 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard sterile dressing
Description: A standard, sterile island dressing
Study NCT03825198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: opioid used for the preoperative analgesia for back surgery during general anaesthesia ( 15 mag)
Study NCT03825198 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sufentanil
Description: opioid used for the preoperative analgesia for back surgery during general anaesthesia ( 15 mag)
Study NCT03825198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: induction agent for general anaesthesia ( 2-3 mg/kg)
Study NCT03825198 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: propofol
Description: induction agent for general anaesthesia ( 2-3 mg/kg)
Study NCT03825198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium Bromide
Description: muscle relaxant used during general anaesthesia ( 0,5 mg/kg)
Study NCT03825198 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Rocuronium Bromide
Description: muscle relaxant used during general anaesthesia ( 0,5 mg/kg)
Study NCT01027871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541
Description: subcutaneous injection of LY2605541 every morning with dose titration based on blood glucose measures for 12 weeks
Study NCT01027871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: subcutaneous injection of insulin glargine every morning with dose titration based on blood glucose measures for 12 weeks
Study NCT00244257 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GMA161
Description: 0.1 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
Study NCT00244257 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GMA161
Description: 0.3 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
Study NCT00244257 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GMA161
Description: 0.6 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
Study NCT00244257 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GMA161
Description: 1.0 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
Study NCT00244257 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GMA161
Description: 3.0 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
Study NCT03589482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Impedance Tomography
Description: Electrical impedance tomography (EIT) is a new technique that enables real-time visualization of the distribution of ventilation at the bedside. This technique allows clinicians and investigators to immediately determine how applying higher or lower PEEP levels affect stress and strain in the lung. The investigators propose to apply this new technique to test a strategy for finding the optimal level of PEEP that prevents lung injury and improves outcomes in critically ill patients.
Study NCT03825198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: inhalation aesthetic used for the maintenance of general anaesthesia
Study NCT03825198 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: sevoflurane
Description: inhalation aesthetic used for the maintenance of general anaesthesia
Study NCT03825198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: postoperative drug for analgesia ( 1 gram 4/day)
Study NCT03825198 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: paracetamol
Description: postoperative drug for analgesia ( 1 gram 4/day)
Study NCT03589482 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ExPRESS-derived PEEP level
Description: The ExPRESS algorithm is a traditional approach to selecting PEEP based on respiratory mechanics.
Study NCT02109679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: multiple doses metformin given as tablet
Study NCT02109679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004
Description: multiple doses BI 187004 given as tablets
Study NCT00550108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethanol lavage
Description: Ethanol lavage of pancreatic cysts.
Study NCT03888924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacille Calmette-Guerin vaccine
Description: One dose (0.1 mL) contains 50 μg of the semi-dry mass of BCG bacilli, i.e. from 150,000 to 600,000 of live BCG bacilli (Bacillus Calmette-Guerin), the Brazilian Moreau substrain.~One ampoule or vial with the powder contains: 0.5 mg (from 1.5 mln to 6 mln) of live BCG bacilli (Bacillus Calmette-Guerin), the Brazilian Moreau substrain.~Powder: monosodium glutamate. Solvent: isotonic solution of sodium chloride.
Study NCT03888924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: isotonic solution of sodium chloride (2mL vials).
Study NCT03834272 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LUM Imaging System
Description: Patients will be injected with one of 3 study doses of LUM015 and tissue will be imaged in vivo with the LUM imaging device.
Study NCT03825198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: non steroidal into inflammation drug used for postoperative analgesia (0,5 mg/kg)
Study NCT03825198 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ketorolac
Description: non steroidal into inflammation drug used for postoperative analgesia (0,5 mg/kg)
Study NCT03825198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine pca
Description: postoperative morphine pomp, controlled by the patient. ( bolus 1 mg, lockout 8 minutes) the solution contains morphine 1 mg/ml + dehydrobenzperidol 0,05 mg/ml
Study NCT03825198 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: morphine pca
Description: postoperative morphine pomp, controlled by the patient. ( bolus 1 mg, lockout 8 minutes) the solution contains morphine 1 mg/ml + dehydrobenzperidol 0,05 mg/ml
Study NCT04283123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Bidet
Description: During the first intervention visit, a licensed contractor will install the bidets in participants' homes. The OT will then educate and train the caregiver and care recipient to successfully use the bidet, and make any modifications to the remote as needed. Throughout the intervention, the OT will use motivational enhancement strategies. The OT will make minor modifications to the remote as needed. A second intervention visit will occur 1-2 weeks post-installation to address any new difficulties. Check-in phone calls will be offered to the caregiver and care recipient if needed.
Study NCT03825198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: drug given during general anaesthesia to prevent postoperative nausea
Study NCT03825198 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dexamethasone
Description: drug given during general anaesthesia to prevent postoperative nausea
Study NCT04283123 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention
Description: Waitlist control
Study NCT05895630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive physical exercise
Description: Interactive remote sessions of physical exercise in groups of 10 patients. The sessions are categorized by level 1, 2 or 3 and the allocation to this level is decided according to a decision tree taking into account the mobility profile (balance and cardiomuscular health). The intervention will last 12 weeks. The sessions will be delivered 3 times per week (Monday, Wednesday, Friday) offering a total of approximately 180 min/week.
Study NCT05895630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video physical exercise
Description: Individual remote sessions of physical exercise based on pre-recorded videos. The video sessions are categorized by level 1, 2 or 3 and the allocation to this level is decided according to a decision tree taking into account the mobility profile (balance and cardiomuscular health). The videos will be delivered 3 times per week (Monday, Wednesday, Friday) offering a total of approximately 180 min/week.
Study NCT03436654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: 240mg daily orally
Study NCT03825198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: loading dose morhine 0,1 mg/kg at the end of surgery
Study NCT03825198 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Morphine
Description: loading dose morhine 0,1 mg/kg at the end of surgery
Study NCT03757520 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pain Pressure Threshold
Description: The pain pressure thresholds (PPTs) will be measured using an pressure algometer commander over potential trigger points (TrPs) on the body for upper fiber of trapezius, and sternocleidomastoid muscle.
Study NCT03757520 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Hand Grip Force
Description: For measuring the grip strength, the subjects will be asked to sit on a chair with their hip joint flexed at 90 degree, and shoulder joint in a neutral position.~The elbow is fixed at 90 degree flexion, forearm in a neutral position, and wrist at 0 to 15 degree radial deviation The test will be performed twice, and the higher value between the two measurements will be selected.
Study NCT04245033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine (DP)
Description: Dihydroartemisinin-Piperaquine (DP) for intermittent preventive treatment of malaria in school children (IPTsc).
Study NCT03436654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: 1000mg daily orally
Study NCT03436654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5mg BID orally
Study NCT03436654 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: A laparoscopic, robotic-assisted, or open approach to RP is permitted at the discretion of the operating surgeon.
Study NCT01688102 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral Vitamin D3
Description: 50,000 units orally, each week x8 weeks; supplemental doses of 50,000 units orally, each month thereafter as needed
Study NCT01688102 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Ultraviolet Light
Description: 16 treatments, 2-3 times weekly over 8 weeks; initial dose 45-75 seconds, whole-body exposure except face and groin, increasing by 10% as tolerated, to a maximum of 4.5 minutes
Study NCT03116204 — intervention group
Intervention type: OTHER
Intervention: Assessment of score SAS
Description: Assessment of a score assessing physical and cognitive activities of patients in follow-up care and rehabilitation departments
Study NCT02413788 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate)
Study NCT02413788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combined exercise
Description: aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate); resisted training in equipment and free weights for 10 minutes with a set of 10 repetitions in quadriceps, triceps and biceps of the arms and legs
Study NCT02413788 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: treadmill
Study NCT02413788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: treadmill
Study NCT01037543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM10460A or placebo or Neulasta
Description: Single SC injection of the appropriate dose of drug ranging from 1.1 mcg/kg to 270 mcg/kg.
Study NCT03436654 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extended Pelvic lymphadenectomy
Description: To be performed concurrently with prostatectomy. Bilateral pelvic lymphadenectomy should include complete removal of all pelvic lymph nodes within the broad template described and includes the external iliac, hypogastric, obturator, and pre-sacral lymph nodes
Study NCT03436654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH agonist/antagonist
Description: Physician's choice, for a total duration not to extend beyond the treatment phase of the protocol or 10 months from the start of investigational agent(s)
Study NCT03436654 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Subjects undergo SBRT in cycle 4, then salvage radiation therapy in cycles 7-8. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity
Study NCT03623074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel spectacle lens design
Description: Use of lenses may reduce the rate of progression of juvenile myopia
Study NCT03623074 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Spectacle lenses
Description: Use of lenses may reduce the rate of progression of juvenile myopia
Study NCT03599635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal bupivacaine
Description: Experimental
Study NCT03599635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Active Comparator
Study NCT01100736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Bosentan 125mg tablets, orally, twice daily for 7 days
Study NCT01100736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitaxsentan
Description: Sitaxsentan 100mg tablets, orally, once daily for 7 days
Study NCT01100736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets taken twice daily, orally, for 7 days (placebo arm) or once daily for 7 days (sitaxsentan arm)
Study NCT01100736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets taken twice daily, orally, for 7 days (placebo arm) or once daily for 7 days (sitaxsentan arm)
Study NCT01100736 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endothelin-3
Description: 5 minute local intra-arterial infusion of endothelin-3 at a rate of rate of 60 pmol/min, during forearm blood flow studies
Study NCT01100736 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Endothelin-3
Description: 5 minute local intra-arterial infusion of endothelin-3 at a rate of rate of 60 pmol/min, during forearm blood flow studies
Study NCT03703596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Anlotinib (12mg QD PO d1-14, 21 days per cycle)
Study NCT01929681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Field Magnetic Stimulation
Description: Low Field Magnetic Stimulation is an electromagnetic technique. It uses low strength electric fields operating at a high frequency.
Study NCT01929681 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low Field Magnetic Stimulation
Description: Low Field Magnetic Stimulation is an electromagnetic technique. It uses low strength electric fields operating at a high frequency.
Study NCT01380613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workshop
Description: 10 session intervention
Study NCT01380613 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Workshop control
Description: 1 session intervention on standard HIV/STD information
Study NCT00325780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: Pitavastatin 4 mg once daily
Study NCT03703596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel (75mg/m2 IV d1, 21 days per cycle)
Study NCT03660488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefixime 400 milligram Oral Capsule [Suprax]
Description: The intervention group will receive Cefixime 400mg, one tablet twice per day, for ten consecutive days
Study NCT03660488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzathine Penicillin G
Description: The control group will receive Benzathine Penicillin G 2.4 Million Units intramuscularly for treatment of syphilis. Penicillin is the indicated treatment for syphilis infection
Study NCT03415854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol (Zemplar)
Description: combination therapy
Study NCT00679744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrimethamine
Description: Pyrimethamine will be given PO once daily for 8 consecutive weeks.
Study NCT02399007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Hip System made in China (SUN, CoCr, Duraloc, Marathon)
Description: SUN Hip stem,CoCr Femoral Head,Duraloc Porocoat Sector acetabular shell,Marathon 10D polyethylene liner (ETO)
Study NCT02399007 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip System made outside of China (Summit, CoCr, Duraloc, Marathon)
Description: Summit Porocoat STD,CoCr Femoral Head,Duraloc Porocoat Sector acetabular shell,Marathon 10D polyethylene liner (ETO)
Study NCT00764504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reverse Shoulder Prosthesis
Description: For subjects with rotator cuff arthropathy and no previous shoulder device implanted.
Study NCT00764504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reverse Shoulder Prosthesis
Description: For subjects with rotator cuff arthropathy and a failed hemi or total shoulder implant.
Study NCT04592250 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study NCT03295461 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SRP+ 10% Emblica officinalis irrigation
Study NCT03295461 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SRP + 0.2% Chlorhexidine irrigation)
Study NCT03295461 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SRP + 0.9% Saline irrigation
Study NCT03295461 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SRP +10% E. officinalis gel application.
Study NCT03295461 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: SRP+ placebo gel application.
Study NCT03292211 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: early mobilization
Description: early out-of-bed activities including supine to sit training, sit on the edge of bed without supporting, standing with hand supporting, stepping while standing etc.within three days after stroke while being monitored by medical equipment.
Study NCT03292211 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: early standard intervention
Description: Conventional early in-bed activities within three days after stroke
Study NCT03480867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Experimental: Registered one arm study Seven days of pre-operative Radiation+Temozolomide followed by surgery plus TMZ, as adjuvant component.for six cycles.
Study NCT03480867 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pre-Operative Radiation
Description: Radiation is given with Temozolomide for 7 days before surgery
Study NCT02724150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole High dose
Description: High regimen of Proton Pump Inhibitors in treatment of bleeding ulcer 80 mg loading dose then 8 mg/h iv for 3 days
Study NCT02724150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole Low dose
Description: low regimen of Proton Pump Inhibitors in treatment bleeding ulcer 80 mg loading dose then 40 mg two times per day for 3 days